Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir

This study examined drug interactions between buprenorphine, a partial opioid agonist used for opioid dependence treatment and pain management, and the protease inhibitors (PIs) darunavir-ritonavir and fosamprenavir-ritonavir.

The pharmacokinetics of buprenorphine and its metabolites and symptoms of opioid withdrawal or excess were compared in opioid-dependent, buprenorphine-naloxone-maintained, human immunodeficiency virus (HIV)-negative volunteers (11 for darunavir-ritonavir and 10 for fosamprenavir-ritonavir) before and after 15 days of PI administration.

Valerie A. Gruber, Petrie M. Rainey, David E. Moody, Gene D. Morse, Qing Ma, Sudha Prathikanti, Patricia A. Pade, Anika A. H. Alvanzo, Elinore F. McCance-Katz
February 1, 2012
Learn More
LinkedIn